Chair Patricia K. Coyle, MD Professor and Vice Chair (Clinical Affairs) Department of Neurology Director, MS Comprehensive Care Center SUNY at Stony Brook Stony Brook, NY
Faculty Andrea Singer, MD, FACP, CCD Director, Women’s Primary Care Director, Bone Densitometry Department of Obstetrics and Gynecology MedStar Georgetown University Hospital Washington, DC
Megan Weigel, DNP, ARNP-C, MSCN Advanced Registered Nurse Practitioner Baptist Neurology Beaches Division Jacksonville Beach, FL
Monica LaCroix-Rubin Patient Advocate Massapequa, NY
AMA PRA Category 1 Credit TM
Multiple sclerosis (MS) is a chronic neurologic disorder with potential for substantial negative impact on quality of life. MS is nearly 3 times more common in women compared with men and is typically diagnosed between the ages of 20 and 50. Since the diagnosis and treatment of MS frequently occur during women’s reproductive years, clinicians often face questions about MS treatment as it relates to family planning, pregnancy, and the postpartum period. A collaborative care model can ensure that the patient is receiving appropriate information and care, and the increasing amount of data pertaining to treatment safety during pregnancy and breastfeeding, the effect of MS on women's health issues, and strategies to mitigate increased risks of relapses will enhance patient care.
. Target Audience
This activity is intended for neurologists, OB/GYNs, primary care physicians, PAs, NPs, nurses, and other clinicians who care for patients and families affected by MS.
Upon completion of this educational activity, the participant should be able to:
Describe the impact of pregnancy on MS disease activity.
Discuss current data on the benefits and risks of MS disease-modifying therapies for women with MS during conception, pregnancy, and breastfeeding.
Review current best approaches for the treatment of sexual dysfunction in women with MS.
Summarize current evidence for the use of hormone therapy for women with MS.
Define strategies that can be used by various members of the multidisciplinary team to support better gynecologic and reproductive health outcomes for women with MS.
It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.
Patricia K. Coyle, MD has disclosed the following:
Research Funding: Actelion, Novartis, Opexa
Consultant: AbbVie, Accordant, Acorda, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi Aventis, Novartis, EMD Serono, Teva
Andrea Singer, MD, FACP, CCD has disclosed the following:
Research Funding: Amgen
Consultant: Amgen, Actavis, Eli Lilly
Speakers Bureau: Amgen, Actavis
Megan Weigel, DNP, ARNP-C, MSCN has disclosed the following:
Consultant: Biogen, Genentech, Genzyme, Mallinckrodt
Speakers Bureau: Acorda, Biogen, EMD Serono, Genzyme, Mallinckrodt, Novartis, Pfizer, Teva
Monica LaCroix-Rubin has nothing to disclose.
Penn State staff involved in the development and review of this activity have nothing to disclose.
Gena Dolson, MCM Education Senior Medical Writer, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling. Credit Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5797-15-T.
Credit is awarded to participants who score 80% or better on the post-test.
The online activity will take approximately 60 minutes to complete. Commercial Support Statements
Supported by an independent educational grant from Biogen.
There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.
Review the intended audience, learning objectives, and author disclosures.
Study the educational content online.
Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Penn State College of Medicine, or Biogen Idec. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.